This study is testing a combination of chemo-immuno therapy called RBM. RBM consists of combination of drugs: rituximab, bendamustine, and melphalan followed by reinfusion of the participants own stem cells which is called autologous stem cell transplant (ASCT). Compared to the standard BEAM regimen, this RBM regimen may or may not be less effective in lymphoma, but will likely have fewer side effects.
SparkCures ID | 1272 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 29 Patients |
Treatments | |
Tags |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Phase I eligibility:
Dose expansion eligibility:
Additional eligibility for both the phase I and dose expansion cohort:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersLearn more about how we work with trial sponsors